TGA examines cancer risk from angiotensin receptor blockers

THE TGA is investigating whether there is a link between angiotensin receptor blockers (ARBs) and cancer, following recent studies showing patients taking ARBs had a small increased risk of the disease.

A spokesperson for the TGA confirmed the organisation was conducting its own evaluation of the evidence and had not offered specific advice on the use of ARBs and potential cancer risk.

Last week the US Food and Drug Administration (FDA) announced that ARBs do not increase cancer risk, following the results of an analysis of 31 randomised controlled trials of more than 150,000 patients taking ARBs compared with other